Replies to post #122065 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

No one willing to sell?

Bid/Ask ratio currently at 64%.

[bas2020]

We're still under the radar. This update was not PR'd and to many we're just another Alz drug waiting to fail.

Only partnership news, in the short term, will wake up the investment community. (or any association with the new FDA regs)

[falconer66a]

Nothing Really New, No Response on The Street

Would have expected stronger reaction to conf./new information.

In fact, nothing of any significance was revealed. Just more of the same stuff. True, and important, of course. But until authentic positive results from real people suffering real diseases (such as Rett, or Parkinson’s in a few months) is revealed, there will be no new articles in newspapers, news websites, etc. Until positive clinical results from any of the three upcoming clinical trials appear, Anavex will continue to be a complete non-story. Reporters can’t be writing stories their editors would not publish, based upon the recent Anavex presentation information. All of it would take too much science back-grounding, trying to tell lay audiences why the info was true and important, although still preliminary (“Expected to be available if FDA gives approval, some time in the future.”)

That sort of story line never makes a broadcast or headline.

Trying to explain to lay audiences the molecular and cellular biology of sigma-1 receptor agonists is beyond common journalism. There have been so many Alzheimer’s drugs that have failed. Anavex surely must be just another. Keep the news to real news (if there is such a thing — I see not much on the evening news broadcasts; just lots of fancy ads for very expensive drugs with 30 seconds of black-box side effects warnings).

I don’t see the share price of AVXL going anywhere until we first read a page-one headline, “New Drug Proves Safe, Effective Against ____, “(name the disease).

[nidan7500]

Now that's a little better.